develop
effect
vaccin
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
still
prioriti
prevent
reemerg
sar
previou
studi
shown
receptorbind
domain
rbd
sarscov
spike
protein
elicit
highli
potent
neutral
antibodi
respons
immun
anim
unknown
whether
rbd
also
induc
protect
immun
anim
model
key
aspect
vaccin
develop
studi
balbc
mice
vaccin
intramuscularli
im
g
rbdfc
rbd
fuse
human
fc
boost
twice
interv
one
time
month
humor
immun
respons
vaccin
mice
investig
month
interv
neutral
titer
produc
antibodi
report
month
postvaccin
mice
challeng
homolog
strain
sarscov
day
last
boost
sacrif
day
challeng
mous
lung
tissu
collect
detect
viral
load
viru
replic
histopatholog
effect
result
show
rbdfc
vaccin
induc
high
titer
sspecif
antibodi
longterm
potent
sarscov
neutral
activ
four
five
vaccin
mice
protect
subsequ
sarscov
challeng
signific
viru
replic
obviou
histopatholog
chang
found
lung
tissu
vaccin
mice
challeng
sarscov
one
vaccin
mous
mild
alveolar
damag
lung
tissu
contrast
high
copi
sarscov
rna
viru
replic
detect
patholog
chang
observ
lung
tissu
control
mice
conclus
find
suggest
rbd
induc
protect
antibodi
sarscov
may
develop
safe
effect
sar
subunit
vaccin
sever
acut
respiratori
syndrom
sar
novel
infecti
diseas
caus
sar
coronaviru
sarscov
led
sever
hundr
death
among
thousand
case
although
sar
success
contain
reemerg
sarscov
anim
reservoir
still
potenti
risk
futur
epidem
support
continu
report
find
sarscovlik
coronaviru
small
anim
civet
raccoon
dog
bat
sar
outbreak
may
also
recur
futur
viru
escap
laboratori
accid
therefor
develop
safe
effect
sar
vaccin
prevent
sarscov
infect
import
issu
current
sar
research
sarscov
caus
agent
sar
contain
genom
encod
nonstructur
replicas
polyprotein
rep
structur
protein
spike
envelop
e
membran
nucleocapsid
n
protein
respons
viru
bind
receptor
angiotensinconvert
see
front
matter
elsevi
ltd
right
reserv
enzym
subsequ
viru
entri
host
cell
protein
sarscov
also
demonstr
main
antigen
induc
high
titer
neutral
antibodi
elicit
protect
immun
infect
challeng
anim
thu
impli
main
target
develop
sar
vaccin
number
vaccin
candid
base
sarscov
report
term
abil
induc
neutral
antibodi
protect
immun
candid
group
inactiv
virusesbas
proteinbas
dnabas
virusbas
vaccin
mani
virus
includ
vsv
rhabdoviru
adenoviru
adenoassoci
viru
aav
modifi
vaccinia
viru
ankara
mva
attenu
parainfluenza
viru
use
express
sarscov
protein
sar
vaccin
candid
bukreyev
et
al
report
vaccin
african
green
monkey
attenu
parainfluenza
viru
encod
sarscov
result
product
sarscovspecif
neutral
antibodi
protect
anim
viru
challeng
find
suggest
protein
sarscov
good
target
develop
sarscov
vaccin
sinc
dnabas
virusbas
vaccin
candid
still
caus
safeti
concern
proteinbas
vaccin
may
altern
candid
inde
fulllength
protein
subunit
could
induc
potent
neutral
antibodi
respons
immun
anim
howev
may
also
elicit
antibodi
enhanc
viru
infect
caus
liver
damag
anim
challeng
sarscov
regard
receptorbind
domain
rbd
fragment
protein
demonstr
major
neutral
determin
impli
ideal
candid
develop
subunit
vaccin
sar
studi
evalu
longterm
immun
respons
protect
immun
sarscov
infect
mous
model
strain
sarscov
genbank
access
propag
vero
cell
condit
biosafeti
level
laboratori
titer
viru
strain
determin
tissuecultur
infecti
dose
tcid
vero
cell
rbd
domain
sarscov
protein
residu
fuse
fc
domain
human
rbdfc
produc
describ
previous
briefli
plasmid
encod
rbdfc
fusion
protein
transfect
cell
use
fugen
transfect
reagent
boehring
mannheim
accord
manufactur
protocol
supernat
harvest
h
posttransfect
recombin
rbdfc
protein
purifi
protein
asepharos
fast
flow
amersham
bioscienc
usa
fulllength
protein
sarscov
urbani
access
express
expressf
insect
cell
recombin
baculoviru
purchas
protein
scienc
corpor
bridgeport
ct
group
five
femal
balbc
mice
age
week
vaccin
intramuscularli
im
g
purifi
rbdfc
resuspend
phosphatebuff
solut
pb
ph
presenc
freund
complet
adjuv
fca
boost
twice
freshli
prepar
emuls
g
immunogen
freund
incomplet
adjuv
fia
interv
mice
boost
third
time
amount
rbdfc
fia
month
first
vaccin
challeng
sarscov
day
later
fig
mice
inject
amount
pb
use
neg
control
group
mous
sera
collect
immun
interv
postvaccin
sera
kept
c
use
mous
sera
test
recombin
sarscov
protein
elisa
briefli
gml
recombin
protein
coat
microtit
plate
corn
costar
acton
carbon
buffer
ph
c
overnight
block
nonfat
milk
serial
dilut
mous
sera
ad
incub
c
h
follow
three
wash
pb
contain
tween
bound
antibodi
detect
hrpconjug
goat
antimous
igg
zyme
south
san
francisco
ca
c
h
three
wash
reaction
visual
addit
substrat
tetramethylbenzidin
tmb
measur
absorb
nm
elisa
plate
reader
victor
multilabel
counter
perkinelm
usa
titer
neutral
antibodi
mous
sera
vaccin
recombin
rbdfc
protein
detect
vero
cell
describ
qu
et
al
briefli
vero
cell
seed
cellswel
cultur
plate
cultur
c
h
form
monolay
serial
twofold
dilut
serum
sampl
incub
tcid
sarscov
strain
c
h
subsequ
ad
monolay
vero
cell
tetrad
cell
infect
tcid
sarscov
without
viru
appli
posit
neg
control
respect
cytopath
effect
cpe
well
observ
daili
record
day
postinfect
neutral
titer
mous
antisera
complet
prevent
cpe
well
calcul
reedmuench
method
five
day
last
boost
rbdfc
mice
anaesthet
isofluran
intranas
inocul
l
dilut
sarscov
strain
tcid
accord
nation
anim
care
use
guidelin
laboratori
vaccin
mice
sacrif
day
challeng
lung
mice
remov
lung
tissu
store
c
virolog
test
fix
paraformaldehyd
store
c
histopatholog
analysi
viral
rna
copi
lung
tissu
determin
qrtpcr
accord
protocol
describ
zhai
et
al
limit
detect
live
viru
lung
sampl
copiesg
briefli
total
rna
extract
mg
lung
tissu
use
rneasi
mini
kit
qiagen
hilden
germani
follow
manu
viru
replic
determin
titrat
inocul
viru
lung
tissu
collect
sacrif
mice
briefli
lung
tissu
homogen
final
concentr
wv
suspens
dulbecco
modifi
eagl
medium
dmem
invitrogen
usa
tissu
homogen
centrifug
filtrat
inocul
monolay
vero
cell
seed
tissuecultur
plate
result
evalu
day
cultur
phasecontrast
microscopi
viral
titer
use
cpebas
tcid
test
calcul
reedmuench
method
viral
titer
express
log
tcid
g
tissu
lowest
detect
limit
log
tcid
g
total
amount
viru
calcul
multipli
weight
lung
tissu
viral
titer
measur
tissu
homogen
lung
tissu
immedi
fix
buffer
paraformaldehyd
embed
paraffin
wax
section
made
thick
mount
slide
histopatholog
chang
caus
sarscov
infect
examin
haematoxylin
eosin
h
e
stain
view
light
microscopi
shown
fig
rbdfc
vaccin
induc
prolong
potent
humor
immun
respons
igg
specif
sarscov
protein
anim
test
elisa
reach
highest
titer
mean
se
month
postvaccin
although
titer
decreas
slightli
afterward
high
titer
sspecif
igg
antibodi
maintain
least
month
drop
end
month
specif
igg
antibodi
increas
rapidli
boost
month
first
vaccin
reach
titer
sarscov
challeng
fig
demonstr
antibodi
induc
vaccin
rbdfc
exhibit
strong
neutral
activ
similar
pattern
elisa
antibodi
rbd
neutral
antibodi
reach
highest
level
month
vaccin
rbdfc
neutral
antibodi
level
slightli
decreas
end
month
drop
less
end
month
titer
neutral
antibodi
sarscov
increas
third
boost
reach
titer
titer
neutral
antibodi
determin
highest
dilut
sera
could
complet
prevent
cpe
least
well
present
geometr
mean
se
five
mous
sera
group
sarscov
challeng
howev
neither
elisa
sspecif
antibodi
neutral
antibodi
detect
mous
sera
control
group
five
day
challeng
sarscov
intranas
rout
mice
sacrif
lung
tissu
collect
viru
rna
copi
lung
tissu
determin
qrtpcr
describ
rna
copiesg
tissu
shown
tabl
viral
rna
copi
rbdfc
group
control
group
neg
correl
titer
neutral
antibodi
sarscov
higher
titer
neutral
antibodi
detect
sera
lower
copi
number
viral
rna
found
lung
tissu
mous
rbdfc
vaccin
group
develop
lowest
titer
neutral
antibodi
show
detect
viral
rna
copi
viral
rna
detect
lung
tissu
four
mice
group
present
higher
titer
neutral
antibodi
similarli
neutral
antibodi
respons
pb
control
group
correl
higher
level
rna
copi
lung
tissu
result
suggest
neutral
antibodi
induc
rbdfc
vaccin
play
import
role
prevent
sarscov
infect
viru
challeng
mice
sarscov
replic
detect
titrat
inocul
viru
lung
tissu
evalu
efficaci
rbdfc
vaccin
protect
sarscov
infect
fig
five
mice
control
group
vaccin
pb
high
titer
viru
replic
lung
sarscov
challeng
howev
mice
vaccin
rbdfc
either
complet
four
five
mice
partial
protect
one
five
mice
show
lower
level
neutral
antibodi
serum
sarscov
challeng
data
indic
vaccin
rbdfc
titer
neutral
antibodi
sera
collect
mous
day
last
vaccin
viru
inocul
determin
rna
copi
lung
tissu
mice
challeng
sarscov
measur
qrtpcr
express
rna
copiesg
lung
tissu
rbdfcvaccin
mice
control
mice
respect
limit
detect
live
viru
lung
copiesg
abl
establish
protect
immun
prevent
mice
subsequ
sarscov
challeng
histopatholog
chang
lung
rbdfc
vaccin
control
mice
observ
h
e
stain
lung
tissu
section
lung
tissu
control
mice
inject
pb
reveal
signific
histopatholog
chang
includ
diffus
alveolar
damag
character
disrupt
alveolar
wall
flood
alveolar
lumina
serosanguin
exud
admix
neutrophil
alveolar
macrophag
thicken
alveolar
wall
line
type
pneumocyt
alveolar
macrophag
alveolar
lumina
fig
howev
except
mous
mild
level
alveolar
damag
lung
tissu
four
rbdfc
vaccin
mice
exhibit
signific
histopatholog
chang
show
similar
histolog
structur
normal
mous
lung
tissu
fig
result
confirm
rbdfc
vaccin
abl
prevent
mice
subsequ
sarscov
infect
develop
effect
safe
sar
vaccin
crucial
prevent
reoccurr
sar
epidem
among
four
structur
protein
sarscov
serv
import
antigen
develop
sar
vaccin
sinc
play
essenti
role
host
cell
tropism
viru
entri
abil
induc
neutral
antibodi
protect
immun
report
shown
neutral
antibodi
protein
protect
vaccin
anim
sarscov
challeng
thu
vaccin
encod
protein
target
humor
immun
responsesneutr
antibodi
indispens
prevent
sarscov
infect
current
report
sar
vaccin
candid
base
fulllength
protein
sarscov
although
fulllength
proteinbas
vaccin
elicit
neutral
antibodi
andor
protect
immun
report
kind
vaccin
may
also
induc
harm
inflammatori
immun
respons
rais
concern
efficaci
safeti
vaccin
contain
encod
fulllength
protein
thu
propos
use
rbd
fragment
protein
rather
fulllength
protein
develop
safe
effect
sar
subunit
vaccin
sinc
contain
major
neutral
epitop
previou
studi
shown
recombin
rbd
induc
high
potent
neutral
antibodi
sarscov
variant
mous
exhibit
mild
histopatholog
damag
lung
tissu
compar
control
mice
mous
reveal
littl
damag
thicken
alveolar
wall
interstiti
mononuclear
cell
lymphocyt
infiltr
congest
markedli
hemorrhag
effus
alveolar
space
lung
tissu
know
whether
rbdbase
vaccin
protect
anim
sarscov
infect
studi
compar
antibodi
respons
protect
immun
mice
vaccin
rbdfc
control
mice
found
rbdfc
elicit
potent
longterm
humor
immun
respons
vaccin
mice
high
titer
sarscov
sspecif
elisa
antibodi
viru
neutral
antibodi
maintain
least
month
although
antibodi
drop
low
level
end
month
titer
rebound
rapidli
mice
reboost
rbdfc
vaccin
mice
protect
sarscov
challeng
sinc
signific
viru
replic
detect
lung
notabl
presenc
high
titer
neutral
antibodi
prerequisit
protect
immun
higher
titer
neutral
antibodi
associ
lower
level
rna
copiesviru
replic
stronger
protect
activ
sarscov
challeng
among
five
mice
vaccin
rbdfc
four
mice
possess
high
titer
neutral
antibodi
exhibit
signific
viru
replic
histopatholog
chang
lung
one
mous
low
sera
neutral
antibodi
titer
show
margin
level
viru
rna
copi
mild
histopatholog
chang
howev
five
mice
undetect
neutral
antibodi
control
group
present
high
level
rna
copiesviru
replic
obviou
histopatholog
chang
lung
result
indic
neutral
antibodi
produc
rbdfc
vaccin
mice
play
signific
role
protect
mice
viru
challeng
without
caus
immunopatholog
damag
summari
vaccin
contain
rbd
sarscov
protein
may
induc
suffici
neutral
antibodi
longterm
protect
immun
sarscov
challeng
establish
mous
model
vaccin
candid
may
overcom
disadvantag
vaccin
candid
mention
protect
vaccin
mice
subsequ
sarscov
challeng
result
suggest
rbdfc
vaccin
develop
ideal
subunit
vaccin
prevent
sar
epidem
